CD5 and CD43 expression are associate with poor prognosis in DLBCL patients

Hui Huang; Zhandong Li; Chuansheng Huang; Jun Rao; Qin Xie; Wenhao Cui; Fangfang Tou; Zhi Zheng

doi:10.1515/med-2018-0089

Artikel Open Access

CD5 and CD43 expression are associate with poor prognosis in DLBCL patients

Hui Huang , Zhandong Li , Chuansheng Huang , Jun Rao , Qin Xie , Wenhao Cui , Fangfang Tou und Zhi Zheng

Veröffentlicht/Copyright: 27. November 2018

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Open Medicine Band 13 Heft 1

Abstract

Objective

To investigate the expression and clinical significance of CD5 and CD43 in diffuse large B cell lymphoma (DLBCL) (unspecified).

Methods

Sixty - five patients with diagnosed DLBCL were enrolled. The expressions of CD5, CD43, CD10, Bcl-6 and Mun-1 were detected by immuno histochemistry. The relationship between CD5 and CD43 and clinicopathological features and prognosis of DLBCL was analyzed.

Results

In sixty - five adult DLBCL patients , 6 cases of DLBCL (9.2%) were CD5 positive, 24 cases of DLBCL (36.9%) were CD43 positive, 5 cases of DLBCL (7.7%) were both CD5 and CD43 positive. 40 cases of DLBCL (61.5%) were CD5 and CD43 negative. CD5 expression was not related to age, sex, clinical stage, type of immunophenotype (Hans typing), location, and whether infected with hepatitis B virus (HBV); CD43 expression was correlated with immunophenotyping and HBV i nfection, but was not correlated with the age, sex, clinical stage, and site. Median survival time was significantly lower in CD5- and CD43- positive DLBCL patients than CD5- and CD43-negative patien ts.

Conclusion

The prognosis of DLBCL patients may be worse with positive CD5 and CD43 expression.

Keywords: CD5; CD43; Diffuse Large B-cell Lymphoma; Prognostic factor

1 Introduction

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma(NHL) and is clinically highly invasive. Based on the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues, DLBCL was divided into three categories: non-specific (NOS), special subtypes and independent diseases according to morphology, immunophenotype, genetics and clinical features [1]. The majority of DLBCL belongs to DLBCL (NOS). This category has significant heterogeneity, which is reflected in the clinical manifestations, histological features, immunophenotype, genetic features and diverse biological behavior, inconsistent response to treatment, and prognosis differences [2]. Among them, the tumor response to chemotherapy and prognosis is the most concern [3]. In recent years, more scholars have studied the prognosis of this tumor, and put forward relevant prognostic indicators, but its clinical significance is still controversial [4, 5, 6]. Therefore, the search for prognostic indicators of DLBCL (NOS) and the further classification of this tumor remains an important clinical issue. With further research, some scholars have suggested that CD5 and CD43 may be adverse prognostic factors of DLBCL [7, 8, 9]. Therefore, we planned to study the expression of biomarker CD5 and CD43 and i ts relationship with the prognosis in 65 patients with DLBCL.

2 Materials and methods

2.1 Patients and samples

There were 65 adult patients enrolled in the research with DLBCL (NOS) from May 2005 to October 2017 at Jiangxi Cancer Hospital (Nanchang, China). Three DHL patients were excluded from the research.

Overall, 45 patients were analyzed. Diagnoses of specimens were made by two independent hematopathologists on the basis of the 2008 WHO classification. In the study, all diagnoses of DLBCLs were treated with RCHOP (rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone)or R-CHOP-based regimens as the first-line therapy. Formalin-fixed and paraffin-embedded tissue blocks were collected, and Immunochemical analysis (IHC) for CD5, CD43, CD10, Bcl-6 and Mum-1 was executed when all patients were at initial diagnosis. Computed tomography (CT) scanning and ⁄ or PETCT scanning were performed to assess initial therapeutic responses after the initial treatment. This study conformed with principles of the Declaration of Helsinki by the ethics review committee of Jiangxi Cancer Hospital (Nanchang, China).

Informed consent: Informed consent has been obtained from all individuals included in this study.

2.2 Immunochemical staining

Formalin-fixed and paraffin-embedded tissue samples were prepared by standardized procedures. Tissue microarrays were used in the tissue samples and evaluations of IHC. Primary antibodies used for IHC included anti-CD5, anti-CD43, anti-CD10, anti-BCL6 and anti-Mum-1 (Fuzhou, China). Two experienced hematopathologists reviewed the immunohistochemistry results in combination with clinical, morphological and immunophenotypes. DLBCL was diagnosed based upon the protein expression of CD10, Bcl-6 and Mum-1 (Hans typing) respectively, according to previous recommended studies.

2.3 Statistical evaluation

The chi-square test (Graphpad prism 7.0 software) was performed to compare the clinicopathological characteristics of the patients, while the P-values ≤ 0.05 was considered statistically significant. Kaplan–Meier’s estimates were used to predict OS (the time from the 1st treatment to the death or the latest follow up) and PFS (the time from the 1st treatment to disease progress) of the patients.

BCL-6 and MUM-1 positive staining localized in the nucleus, while CD5, CD10 and CD43-positive staining localized in the cellular membrane with brownish yellow granules. Semi-quantitative analysis showed that the tumor cells with indices ≥30% were correctly located, and clear staining was positive [10].

3 Results

3.1 Patient characteristics

Among the enrolled 65 patients, the age ranged from 17 to 85 years. The median age was 62 years, and the follow up interval was from 2 to 127 months. The median follow-up period was 40 months. The clinical features of DLBCLs are shown in Table 1. In these 65 patients, forty-one (63.07%) were men, and twenty-four (36.93%) were women. Twenty-eight patients (43.08%) examined for lactate dehydrogenase showed high levels, and IPI scores of all patients (100.00%) were 0–2. Moreover, forty-nine patients (75.38%) were at late-stage III–IV (Ann Arbor stage). Thirty-one patients (50.77%) experienced complete response or partial response.

Table 1

Characteristics of patients with diffuse large B-cell lymphoma (n = 65)

Patient characteristic	n	%
Sex
Male	41	63.07
Female	24	36.93
Age, median (range), years
≥61	36	55.38
≤61	29	44.62
Stage
I ⁄ II	16	24.62
III ⁄ IV	49	75.38
Serum LDH
Normal	37	56.92
Elevated	28	43.08
ECOG performance status
0–2	65	100.00
3–5	0
Extranodal sites
≥2	1	1.54
<2	25	98.46
IPI score
IPI 0-2	40	61.54
IPI 3-5	25	38.46
Initial therapy response
Complete response	7	10.77
Partial response	26	40.00
Stable disease	25	38.46
Progressive disease	7	10.77

ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase.

3.2 Immunophenotyping, expression of CD5 and CD43 in DLBCL

There were 19 DLBCL patients (29.23%) diagnosed with germinal center B-cell type, and 16 DLBCL patients (70.77%) were diagnosed with non- germinal center B-cell type in the 65 patients. The positive expression of CD5 and CD43 showed a weakly positive expression of tumor cell membrane in Figure 1. Table 2 shows CD5 positive expression in 6 cases (9.2%), CD43 positive expression in 24 cases (36.9%), and CD5 and CD43 positive expression in 5 cases (7.7%), CD5 and CD43 negative in 40 cases (61.5%).

Figure 1

CD5 and CD43 expression in DLBCL patients (×40). a: CD5 positive expression in DLBCL patients; b: CD43 positive expression in DLBCL patients.

Table 2

Expression of CD5 and CD43 in diffuse large B-cell lymphoma (n = 65)

All patients	CD43+	CD43-	P-value
CD5+	5	1	-
CD5-	19	40	-
Total	24	41	0.020

3.3 The relationship between CD5 and CD43 expression and clinicopathological features

The positive expression of CD5 was not related to age, sex, site, clinical stage, immunophenotype, and HBV infection. The positive expression of CD43 was related to the immunophenotyping and HBV infection, but not to the age, sex, site, or clinical stage in Table 3.

Table 3

The relationship between CD5 and CD43 expression and clinicopathological features (n = 65)

	CD5+	CD5-	P-value	CD43+	CD43-	P-value
All patients	6	59	-	24	41	-
<60 years	3	26	0.781	12	17	0.504
≥60 years	3	33		12	24
Male	5	37	0.314	17	24	0.321
Female	1	22		7	17
Intranodal sites	2	37	0.162	18	21	0.059
	4	22		6	20
Extranodal sites	2	14	0.603	6	10	0.956
I-II Stage	4	45		18	31
III-IV Stage	1	18	0.478	3	16	0.023
GCB	5	41		21	25
non-GCB
HBsAg+	2	10	0.324	9	3	0.002
HBsAg-	4	49		15	38

3.4 Survival analysis and univariate and multivariate analysis

The median follow-up time of 45 DLBCL (NOS) patients was 33.0 months. The median survival time (MST) of CD5 positive DLBCLs was 11.6 months, and the MST of CD5 negative DLBCLs was 32.8 months. The CD5+ group had a significantly worse MST than the CD5- group (P =0.001), as shown in Figure 2a The MST of CD43-positive DLBCLs was 25.0 months, and the MST of CD43-negative DLBCLs was 34.0 months. the MST of patients with CD43-negative DLBCL was longer than that of CD43-positive (P = 0.003), as shown in Figure 2b

Figure 2

Survival analysis according to the CD5 and CD43 expression in DLBCL patients. a: The MST of CD5 positive DLBCL patients was 11.6 months, and the MST of CD5 negative DLBCL patients was 32.8 months. The difference between the two groups was statistically significant (P=0.001); b: The MST of CD43-positive DLBCL patients was 20.2 months, and the MST of CD43-negative DLBCL patients was 36.4 months. The difference was statistically significant (P=0.003).

4 Discussion

DLBCL (NOS) has significant heterogeneity. It is one of the more urgent problems to re-classify this tumor to meet the clinical choice of treatment options and prognosis [11]. In recent years, domestic and foreign scholars are actively exploring this problem. The International prognostic index (IPI) is a commonly used clinical reference index for predicting the prognosis of DLBCL. However, patients with the same IPI score have different responses and prognoses to the same chemotherapy regimen [12]. Therefore, to explore the relevant indicators of DLBCL prognosis has always been one of the focuses of scholars at home and abroad.

CD5 is one of the T lymphocyte markers but is expressed in both fetal cord blood and spleen B lymphocytes and 5% -10% of normal adult peripheral blood B lymphocytes. In addition, CD5 is also expressed in some B cell lymphomas, such as partial follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma, Burkitt’s lymphoma and diffuse large B cell lymphoma. It has been reported in the literature that primary CD5-positive DLBCL accounts for 5% -10% of DLBCL (NOS) and has clinical features that are different from those of CD5-negative DLBCL and is one of the unfavorable independent prognostic factors. Primary CD5 positive DLBCL is more common in older women, and has high serum LDH levels, high IPI, high central nervous system recurrence rate and low survival rate [13]. The results of this group of patients showed that the positive expression rate of CD5 in DLBCL was 9.2%. The positive expression of CD5 did not show correlation with age, sex, clinical stage, type of immunophenotype (Hans), location and HBsAg, but may be due to the number of CD5-positive DLBCL cases in this group being too small,. However, the results of the study indicated that the MST of CD5-positive DLBCLs was obviously lower than that of CD5-negative, demonstrating that CD5-positive expression is a poor prognostic marker for patients with DLBCL. CD43 is a transmembrane glycoprotein that is expressed on different lymphoid hematopoietic cells, including certain B lymphocyte subsets. Studies have shown that the positive expression rate of CD43 in DLBCL is between 19.0% and 29.4%, which is correlated with non-GCB and poor prognosis [9, 14]. The results of this group of data show that the positive expression rate of CD43 in DLBCL was 36.9%, higher than the relevant reports. The MST of patients with CD43-positive DLBCL was apparently lower than that of CD43-negative patients, similar to the one reported in the studies 9, 14, 15, and associated with Hans-classified non-GCB and HBsAg + as one of the adverse prognostic factors in patients with DLBCL, but not with age, gender, clinical stage and location. Reported in the literature, HBsAg positive is more common in non-GCB patients, such as patients with poor prognosis, and the relationship between HBsAg and CD43 expression is not clear [16].

CD5-positive DLBCL always occurs in the elderly, showing an invasive course, prone to central recurrence, with high mortality and poor prognosis. It may represent an independent disease type in DLBCL. The pathogenesis of this disease is still unknown, and standard treatment for CD5-positive DLBCL is unform. CD5-positive DLBCL patients have moderately aggressive lymphomas, requiring systemic chemotherapy-based combination therapy. Rituximab combined with a stronger chemotherapy regimen may benefit such patients, and targeted therapy for CD5 may be improved in the future [17]. A potential therapeutic approach to the cure rate of CD5-positive DLBCL, focus on how to improve the clinical cure rate and reduce recurrence of such patients, requires further research. The development of the best treatment model requires confirmation of data from a large sample of prospective randomized controlled trials.

In conclusion, our study indicated that the prognosis of CD5 and CD43 positive in DLBCL may be worse.

# These authors contributed equally to this work.

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 81260592). In part by a Science and Technology Support Grant 20142BBG70081 from the Jiangxi Province, China; The funding institutes had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing financial interests: The authors declare no competing financial interest.

Reference

[1] Swerdlow, Steven H: WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer; 2008Suche in Google Scholar

[2] Amin AD, Peters TL, Li L, Rajan SS, Choudhari R, Puvvada SD, Schatz JH: Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harbor Molecular Case Studies 2017, 3(3):a00171910.1101/mcs.a001719Suche in Google Scholar PubMed PubMed Central

[3] Yong HJ, Cheolwon S, Seog KW: Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000res 2016, 5:193310.12688/f1000research.8790.1Suche in Google Scholar PubMed PubMed Central

[4] Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S: Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. Journal of geriatric oncology 2015, 6(2):141-15210.1016/j.jgo.2014.11.004Suche in Google Scholar PubMed

[5] Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M: MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer research 2014, 34(2):557-564Suche in Google Scholar

[6] Yu XN, Chen BA: [Progress of microRNA in diagnosis and prognosis of diffuse large B cell lymphoma-review]. Zhongguo shi yan xue ye xue za zhi 2013, 21(5):1351-1355Suche in Google Scholar

[7] Chuang WY, Chang H, Shih LY, Wang PN, Chang YS, Lin TL, Hung YS, Yeh CJ, Ueng SH, Tang TC: CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Archiv 2015, 467(5):571-58210.1007/s00428-015-1845-1Suche in Google Scholar PubMed

[8] Kim HY, Jang MA, Kim HJ, Kim SJ, Kim WS, Kim SH: Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood research 2017, 52(3):193-19910.5045/br.2017.52.3.193Suche in Google Scholar PubMed PubMed Central

[9] Ma XB, Zheng Y, Yuan HP, Jiang J, Wang YP: CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. Human pathology 2015, 46(4):593-59910.1016/j.humpath.2015.01.002Suche in Google Scholar PubMed

[10] Reber R, Banz Y, Garamvölgyi E, Perren A, Novak U: Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. Swiss Medical Weekly 2013, 143(143):w1374810.4414/smw.2013.13748Suche in Google Scholar PubMed

[11] Sujobert P, Salles G, Bachy E: Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? Hematology/oncology Clinics of North America 2016, 30(6):116310.1016/j.hoc.2016.07.001Suche in Google Scholar PubMed

[12] Lee H, Kim YR, Kim SJ, Park Y, Eom HS, Oh SY, Kim HJ, Kang HJ, Lee WS, Moon JH: Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. Annals of Hematology 2017:1–910.1007/s00277-017-3107-6Suche in Google Scholar PubMed

[13] Jain P, Fayad LE, Rosenwald A, Young KH, O’Brien S: Recent advances in de novo CD5 + diffuse large B cell lymphoma. American Journal of Hematology 2013, 88(9):79810.1002/ajh.23467Suche in Google Scholar PubMed

[14] Mitrovic Z, Ilic I, Nola M, Aurer I, Sonicki Z, Basic-Kinda S, Radman I, Ajdukovic R, Labar B: CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. Clinical lymphoma & myeloma 2009, 9(2):133-13710.3816/CLM.2009.n.033Suche in Google Scholar PubMed

[15] Mitrovic Z, Iqbal J, Fu K, Smith LM, Bast M, Greiner TC, Aoun P, Armitage JO, Vose JM, Weisenburger DD et al: CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. British journal of haematology 2013, 162(1):87-9210.1111/bjh.12356Suche in Google Scholar PubMed

[16] Deng L, Song Y, Young KH, Hu S, Ning D, Song W, Li X, Shi Y, Huang H, Liu W: Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 2015, 6(28):25061-2507510.18632/oncotarget.4677Suche in Google Scholar PubMed PubMed Central

[17] Dalloul A: CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009, 8(4):349-35310.1016/j.autrev.2008.11.007Suche in Google Scholar PubMed

Received: 2018-06-14

Accepted: 2018-08-09

Published Online: 2018-11-27

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Artikel in diesem Heft

https://doi.org/10.1515/med-2018-0089

Schlagwörter für diesen Artikel

CD5; CD43; Diffuse Large B-cell Lymphoma; Prognostic factor

Creative Commons

BY-NC-ND 4.0